Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the U.K.: A prospective study

Clinical Oncology

Volumn 16, Issue 2, 2004, Pages 95-104

  Henderson, Alastair ^a,b,c   Ismail, A K A ^a   Cunningham, M ^a   Aldridge, S ^a   Loverock, L ^a   Langley, S E M ^a   Laing, R W ^a  

^a St Luke's Cancer Centre   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; International Prostate Symptom Scores (IPSS); Prostate cancer; Prostate specific antigen; Toxicity; Urinary symptoms; Urodynamics

Indexed keywords

ALFUZOSIN; ANALGESIC AGENT; BICALUTAMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GONADORELIN DERIVATIVE; IODINE 125; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; BLADDER SURGERY; BRACHYTHERAPY; CANCER CENTER; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DETERIORATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EARLY CANCER; ENTEROPATHY; FOLLOW UP; HUMAN; INTERSTITIUM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICTURITION; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PERINEUM; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROCTITIS; PROGNOSIS; PROSTATE CANCER; RECTUM HEMORRHAGE; RISK FACTOR; SCORING SYSTEM; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNITED KINGDOM; URINARY FREQUENCY; URINARY TRACT DISEASE; URINE CATHETER; URINE RETENTION; URODYNAMICS;

EID: 1542398900     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2003.11.006     Document Type: Article

References (33)

1. BAUS. Analyses of minimum data set for urological cancer. London: BAUS, 2001:39.
2. Ravichandran S, Dasgupta P, Booth CM. Radical prostatectomy in Britain and Ireland at the millennium. BJU Int 2002;90:420-422; discussion 422-423.
3. 125iodine implantation for localized carcinoma of the prostate. BJU Int 1999;83:53-56.
4. 125Iodine prostate brachytherapy: Outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics. BJU Int 2002; 90:567-572.
5. Bates TS, Wright MP, Gillatt DA. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. Eur Urol 1998; 33:165-169.
6. Walsh PC, Marschke P, Ricker D, et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55:58-61.
7. Ragde H, Korb LJ, Elgamal AA, et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-141.
8. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46:839-850.
9. 125I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40.
10. Langley SEM, Laing RW. Prostate brachytherapy has come of age: A review of the technique and results. Br J Urol 2002;89:1-14.
11. Potters L, Kattan MW, Reddy CA, et al. Monotherapy for stage T1/T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54(252):9.
12. Kupelian PA, Potters L, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2002;54(252):38.
13. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-321.
14. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: Three simple indices to define bladder voiding function. BJU Int 1999;84:14-15.
15. Patel MI, Watts W, Grant A. The optimal form of urinary drainage after acute retention of urine. BJU Int 2001;88:26-29.
16. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-326.
17. Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893-902.
18. Bucci J, Spadinger I, Hilts M, et al. Urethral and periurethral dosimetry in prostate brachytherapy: Is there a convenient surrogate? Int J Radiat Oncol Biol Phys 2002;54:1235-1242.
19. Crook J, McLean M, Catton C, et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
20. Bucci J, Morris WJ, Keyes M, et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53:91-98.
21. Altman DG. Practical statistics for medical research, 1st edn. London: Chapman and Hall, 1991.
22. Barry MJ, O'Leary MP. Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 1995;22:299-307.
23. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-1382.
24. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465-471.
25. Fulmer BR, Bissonette EA, Petroni GR, et al. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: Comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001;91:2046-2055.
26. Potters L, Torre T, Fearn PA, et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-1242.
27. Critz FA, Levinson AK, Williams WH, et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997;49:322-326.
28. Hanlon AL, Diratzouian H, Hanks GE. Post-treatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53:297-303.
29. Merrick GS, Butler WM, Galbreath RW, et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41-48.
30. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
31. Lee W, Moughan J, Owen J, et al. The 1999 patterns of care survey of radiation therapy in localized prostate cancer-a comprehensive survey of prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 2003;57:S226.
32. 103Pd seed implantation. Mol Urol 2000;4:163-168; discussion 169-170.
33. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444-452.